Adjuvant Immunotherapy After Resected Melanoma : Survival Outcomes, Prognostic Factors and Patterns of Relapse
Martinez-Recio, Sergio (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Molina-Pérez, Maria Alejandra (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Muñoz Couselo, Eva (Vall d'Hebron Institut d'Oncologia)
Sevillano-Tripero, Alberto R. (Hospital Universitario de Getafe (Madrid))
Aya, Francisco (Hospital Clínic i Provincial de Barcelona)
Arance, Ana (Hospital Clínic i Provincial de Barcelona)
Orrillo, Mayra (Institut Català d'Oncologia ICO)
Martin-Liberal, Juan (Institut Català d'Oncologia ICO)
Fernández-Morales, Luis A. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Lesta, Rocio (Hospital Universitario de A Coruña (CHUAC))
Quindós-Varela, María (Hospital Universitario de A Coruña (CHUAC))
Nieva, Maria (Hospital del Mar-Parc Salut Mar)
Vidal, Joana (Hospital del Mar (Barcelona, Catalunya))
Martinez-Perez, Daniel (Hospital Universitario Central de Asturias)
Barba Joaquin, Andrés (Institut de Recerca Sant Pau)
Majem, Margarita (Institut de Recerca Sant Pau)
Universitat Autònoma de Barcelona

Date:	2025
Abstract:	Anti-PD-1-based immunotherapy has improved outcomes in stage IIB to IV resected melanoma patients in clinical trials. However, little is known about real-world outcomes, prognostic factors and patterns of relapse. This is a retrospective multicenter observational study including patients with resected melanoma treated with subsequent anti-PD-1-based adjuvant immunotherapy. Data on clinical and demographic characteristics, delivered treatment, prognostic factors, time and pattern of relapse were collected. We included 245 patients from eight centers; 4% of patients were at stage IIB-C, 80% at stage IIIA-D and 16% at stage IV. Recurrence-free survival (RFS) rates at 18 and 36 months were 60% and 48%, respectively, with a median RFS of 33. 7 months. Prognostic factors associated with recurrence were melanoma primary site (HR 2. 64, 95% CI 1. 15-6. 01) and starting adjuvant therapy more than 12 weeks after the last resection (HR 1. 68, 95% CI 1. 13-2. 5); presence of serious immune-related adverse events was associated with better RFS (HR 0. 4, 95% CI 0. 19-0. 87). Early relapses accounted for 63% of the total recurrences, with a higher number of metastatic sites (18%); in contrast, late relapses presented more frequently with brain metastases (20%). In our patients with resected melanoma who underwent anti-PD-1-based adjuvant immunotherapy, survival outcomes were worse than those reported in clinical trials. Primary melanoma site and time interval between the last resection and the start of adjuvant therapy were associated with survival.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Adjuvant immunotherapy ; Melanoma ; Patterns of relapse ; Prognostic factors ; Survival outcomes
Published in:	Cancers, Vol. 17 Núm. 1 (january 2025) , p. 143, ISSN 2072-6694

DOI: 10.3390/cancers17010143
PMID: 39796770

14 p, 1.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles